Neurizon Completes GMP Tablet Registration Batches
Filed with ASX · · 2 pages · English
• Manufacture of three registration batches of NUZ-001 tablets was successfully completed ahead of schedule, marking a key milestone towards regulatory submissions with the FDA and commercialisation • Manufacturing undertaken by Catalent, a leading global contract manufacturer, utilising full-scale commercial processes and equipment, compliant with FDA and ICH guidelines • Registration batches man
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Elanco executive appointed as Neurizon's Board Observer
- Neurizon to present Q1 FY2026 Results
- Australian Patent Granted for NUZ-001
- FDA Lifts Clinical Hold on NUZ-001
- Neurizon Raises $5m via Institutional Placement
Later from Neurizon Therapeutics
- FDA Clears NUZ-001 for Entry into HEALEY ALS Platform Trial
- Trading Halt
- Equity Raising Presentation
- New Funding Secured for HEALEY ALS Platform Trial
- Regulatory and Development Update
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics